Skip to main content
SpringerLink
Log in

Preventing Long Term Complications

Implications for Combination Therapy with Acarbose

  • Published:
Drugs Aims and scope Submit manuscript

Summary

Long term complications continue to be the major source of morbidity and mortality in patients with diabetes. Acarbose could potentially help to reduce diabetic complications if it improved glucose control, reduced lipid levels and hyperinsulinaemia. Acarbose has been shown to effectively reduce postprandial hyperglycaemia and haemoglobin A1c. This effect might be helpful in patients with insulin-dependent diabetes mellitus, as insulin injections do not provide complete control of rises in postprandial glucose levels, and in patients with non-insulin-dependent diabetes mellitus, because it simplifies the treatment programme. If improved control is shown to reduce complications, acarbose may be helpful. Although acarbose does not reduce hyperinsulinaemia, it reduces lipid levels and thus could reduce the risk of atherosclerosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • American Diabetes Association. Consensus statement: role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care 12: 573–579, 1989

    Google Scholar 

  • Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. New England Journal of Medicine 318: 1315–1321, 1988

    Article  PubMed  CAS  Google Scholar 

  • Clissold SP, Edwards C. Acarbose: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 35: 214–243, 1988

    Article  PubMed  CAS  Google Scholar 

  • Cohen AM, Rosenmann E. Acarbose treatment and diabetic nephropathy in the Cohen diabetic rat. Hormone Metabolism Research 22: 511–515, 1990

    Article  CAS  Google Scholar 

  • Covet C, Ulmer M, Hamdaovi M, Bau HM, Debry G. Metabolic effects of acarbose in healthy men. European Journal of Clinical Nutrition 43: 187–196, 1989

    Google Scholar 

  • DCCT Research Group. Diabetes Control and Complications Trial (DCCT): results of feasibility study. Diabetes Care 10: 1–19, 1987

    Article  Google Scholar 

  • DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14: 173–194, 1991

    Article  PubMed  CAS  Google Scholar 

  • Engerman RL, Kern TS. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes 36: 808–812, 1987

    Article  PubMed  CAS  Google Scholar 

  • Feldt-Rasmussen B, Mathiesen ER, Jensen T, Lauritzen T, Deckert T. Effect of improved metabolic control on loss of kidney function in type I (insulin dependent) diabetic patients: an update of the Steno studies. Diabetologia 34: 164–170, 1991

    Article  PubMed  CAS  Google Scholar 

  • Fontbonne AM, Eschwége EM. Insulin and cardiovascular disease: Paris prospective study. Diabetes Care 14: 461–469, 1991

    Article  PubMed  CAS  Google Scholar 

  • Greene DA, Lattimer SA, Sima AAF. Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. New England Journal of Medicine 316: 599–606, 1987

    Article  PubMed  CAS  Google Scholar 

  • Hanefeld M, Fischer S, Schmechel H, Rothe G, Schulze J, et al. Diabetes intervention study: multi-intervention trial in newly diagnosed NIDDM. Diabetes Care 14: 308–317, 1991

    Article  PubMed  CAS  Google Scholar 

  • Innerfield R, Coniff RF, Shapiro JA, Collins S. A multicentre randomized comparative study of the efficacy of diet alone, acarbose (BAY g 5421) and diet, tolbutamide and diet, and acarbose (BAY g 5421) together with tolbutamide in the treatment of non-insulin-dependent (Type II) diabetes mellitus. Miles Medical Research Report Number 0992, 1989

  • Lebovitz HE. Oral antidiabetic agents: the emergence of α-glucosidase inhibitors. Drugs 44 (Suppl. 3): 21–28, 1992

    Article  PubMed  Google Scholar 

  • Lorenz R, Siebert C, Geary P, Santiago J, Heyse S. Epidemiology of severe hypoglycemia in the DCCT. Diabetes 37 (Suppl. 1): 3A, 1988

    Article  Google Scholar 

  • Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4400 patients observed between 1947 and 1973. Diabetes Care 1: 168–188, 252-263, 1978

    Google Scholar 

  • Pyörälä K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 2: 131–141, 1979

    Article  PubMed  Google Scholar 

  • Reaven GM. Banting Lecture 1988: role of insulin resistance in human disease. Diabetes 37: 1595–1607, 1988

    Article  PubMed  CAS  Google Scholar 

  • Reaven GM. Insulin resistance, hyperinsulinemia, hypertriglyceridemia, and hypertension: parallels between human disease and rodent models. Diabetes Care 14: 195–202, 1991

    Article  PubMed  CAS  Google Scholar 

  • Reaven GM, Lardinois CK, Greenfield MS, Schwartz HC, Vreman HJ. Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas. Diabetes Care 13 (Suppl. 3): 32–36, 1990

    PubMed  Google Scholar 

  • Ricordi C, Tzakis A, Alejandro R, Zeng Y, Demetris AJ, et al. Detection of pancreatic islet tissue following islet allotransplantation in man. Transplantation 52: 1079–1107, 1991

    Article  PubMed  CAS  Google Scholar 

  • Schnack C, Prager RJF, Winkler J, Klauser RM, Schneider BG, et al. Effects of 8-week alpha-glucosidase inhibition on metabolic control. C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled Type II diabetic patients. Diabetes Care 12: 537–543, 1989

    CAS  Google Scholar 

  • Service FJ, Zimmerman BR, Rizza RA, Velosa JA, Frohnert PP, et al. Long-term metabolic control of IDDM who have received pancreatic allografts. Poster: Third International Congress on Pancreatic and Islet Transplantation, Lyon, June 1991

    Google Scholar 

  • Tzakis A, Ricordi C, Alejandro R, et al. Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet 336: 402, 1990

    Article  PubMed  CAS  Google Scholar 

  • Walter-Sack IE, Wolfram G, Zollner N. Effects of acarbose on serum lipoproteins in healthy individuals during prolonged administration of a fiber-free formula diet. Annals of Nutrition Metabolism 33: 100–107, 1989

    Article  PubMed  CAS  Google Scholar 

  • Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 2: 154–160, 1979

    Article  PubMed  CAS  Google Scholar 

  • Zimmerman BR. Current status of aldose reductase inhibitors. Diabetes Care 10: 123–125, 1987

    PubMed  CAS  Google Scholar 

  • Zimmerman BR. Influence of the degree of control of diabetes on the prevention, postponement, and amelioration of late complications. Drugs 38: 941–946, 1989

    Article  PubMed  CAS  Google Scholar 

  • Zimmerman BR, Palumbo PJ, O’Fallon WM, Ellefson RD, Osmundson PJ, et al. A prospective study of peripheral occlusive arterial disease in diabetes. III. Initial lipid and lipoprotein findings. Mayo Clinic Proceedings 56: 233–242, 1981

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Mayo Clinic, Rochester, Minnesota, USA

    Bruce R. Zimmerman

Authors
  1. Bruce R. Zimmerman
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Manuscript submitted June 1991.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zimmerman, B.R. Preventing Long Term Complications. Drugs 44 (Suppl 3), 54–60 (1992). https://doi.org/10.2165/00003495-199200443-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199200443-00008

Keywords

Search

Navigation